Integrating TCIM into mainstream care

Work on traditional, complementary and integrative medicine is moving from prevalence estimates towards questions of safety, regulation, practitioner communication and equitable integration within formal health systems.

Field overview · Compiled August 2026. Written as a general orientation to the literature rather than a summary of my own findings, and not as clinical guidance.

Traditional, complementary and integrative medicine (TCIM) is used by a substantial share of the population across high-income countries, although prevalence estimates vary widely with how “use” is defined and which modalities are counted.¹ Nationally representative Australian survey data show these products and practitioner services are generally used alongside conventional care rather than in place of it.² Once that pattern is established, the interesting research questions stop being about prevalence and start being about the interface: what happens when two systems of care act on the same patient without communicating.

Disclosure is the clearest example. Pooled evidence indicates that a large proportion of people using complementary medicine do not tell their treating clinician, and that non-disclosure is patterned rather than random.³ The consequence is not primarily direct toxicity. The more common risks are indirect — delayed presentation, conventional treatment quietly discontinued, interactions never assessed because the exposure is invisible in the record.⁴ That reframing matters, because it moves the safety question away from whether a given therapy works and towards how information moves through a health system.

Regulation is the second live thread. Who may practise, under what title, and with what accountability differs sharply between jurisdictions and between modalities within the same jurisdiction. Policy borrowed wholesale from conventional professional regulation tends to fit traditional practice poorly, and the argument for distinct policy-making guidelines is now well developed.⁵ The World Health Organization has pushed this onto the international agenda through its traditional medicine strategy and, more recently, the Global Traditional Medicine Centre, both of which frame integration as a health-systems and evidence problem rather than a question of legitimacy.^6,7

Funding and evidence capacity is the third. An analysis of global research funding for TCIM found investment that is modest and unevenly distributed relative to how widely these therapies are used, and concentrated in a small number of countries and modalities.⁸ This produces a familiar circularity: integration is resisted for want of high-quality evidence, and high-quality evidence is difficult to generate without funding proportionate to use.

Methodologically, the field is also arguing with itself about design. Whole-system and practitioner-delivered interventions do not decompose neatly into a single active ingredient, so a trial built around isolating one is often testing something other than what patients actually receive. Much of the current methodological energy sits in pragmatic designs, in measuring the practitioner relationship as part of the intervention, and in approaches that treat context as data rather than noise.

Underneath all of it is equity. TCIM includes Indigenous and culturally embedded traditions whose knowledge holders are not always the people who benefit from the research or the regulation. Integration that treats those traditions purely as a set of interventions to be tested tends to reproduce the imbalance it claims to resolve, which is why governance, consent and benefit-sharing now appear in this literature about as often as efficacy does.